Home Tags Complete Response Letter

Tag: Complete Response Letter

U.S. Food and Drug Administration Rejects Sacituzumab Govitecan

Peter Hofland
The U.S. Food and Drug Administration (FDA) has rejected sacituzumab govitecan also known as IMMU-132, a novel, investigational, antibody-drug conjugate or ADC consisting of...
ADC Review, Journal of Antibody-drug Conjugates
ADC Review, Journal of Antibody-drug Conjugates (ISSN 2327-0152) is an international peer-reviewed publication designed to serve the needs of a diverse community of individuals including academia, life sciences, pharma, research, clinicians and physicians. Along with regulatory affairs, we also cover government authorities and representatives from payers to policymakers.

Latest

Peer Review

© 2013-2020 Sunvalley Communication, LLC. All Rights Reserved.

X